<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01053312</url>
  </required_header>
  <id_info>
    <org_study_id>GE 067-008</org_study_id>
    <nct_id>NCT01053312</nct_id>
  </id_info>
  <brief_title>PET Imaging of Brain Amyloid in Normal Pressure Hydrocephalus</brief_title>
  <official_title>A Principal, Open-Label, Single Center Study to Validate the Detection of Cerebral Cortical Amyloid With Flutemetamol (18F) Injection in Subjects Previously Biopsied</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>i3 Statprobe</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GE Healthcare</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the level of association between the quantitative estimates of
      brain uptake of [18F]flutemetamol and the quantitative immunohistochemical estimates of
      amyloid levels in biopsy samples previously obtained during shunt placement in patients who
      have normal pressure hydrocephalus (NPH).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantitative Estimates of Brain Uptake [18F]Flutemetamol and the Quantitative Immunohistochemical (IHC) Estimates of Amyloid Levels in Biopsy Samples Previously Obtained.</measure>
    <time_frame>Post-contrast administration</time_frame>
    <description>Radiotracers have enabled the in-vivo imaging of amyloid-beta plaques in the brain, one of the histopathologic hallmarks of Alzheimer's disease (AD). Standardized uptake value ratio SUVR)is the quantitive measure of specific tracer uptake, normalized for the non-specific mean uptake in a reference region. SUVR is calculated as SUV_voi/SUV_ref with SUV being the integrated activity over a given time period for the volume of interest (SUV_voi) or reference region (SUV_ref). VOI means volume of interest and REF means reference region.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparsion Between Brain Uptake of [18F] Flutemetamol Amyloid Level From Immunohistochemistry Assay and a Stained Biopsy Tissue Specimen.</measure>
    <time_frame>Post-contrast administration</time_frame>
    <description>This was an amyloid level estimate measured by Immunohistochemistry assay to determine the percentage of plaque area for mAb NAB228. The Immuno-histo chemical reagent was monoclonal antibody (mAB) NAB228. This is a percentage of the area of the biopsy tissue specimen that stains positive for amyloid using NAB228.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantitative Estimates of Amyloid Levels ( Percent % Plaque Load) for the Following 7 Subjects</measure>
    <time_frame>Post-contrast Administration</time_frame>
    <description>Using the Precent area of Plaque values from the Primary Anaylsis, determine the association between cerebral cortical uptake of [18F] flutemetamol (as contralateral, ipsilateral, and composite SUVR values) and Immunohistochemical and histochemical-based estimates of amyloid.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Normal Pressure Hydrocephalus</condition>
  <arm_group>
    <arm_group_label>1 flutemetamol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F] Flutemetamol</intervention_name>
    <description>All subjects will receive an intravenous (IV) dose of [18F]flutemetamol (less than 10µg flutemetamol). The nominal activity of a single administration of [18F]flutemetamol will be 185 megabecquerels (MBq).</description>
    <arm_group_label>1 flutemetamol</arm_group_label>
    <other_name>Flutemetamol</other_name>
    <other_name>AH110690</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject is 50 years old or older.

          -  The subject has had a frontal lobe cortical biopsy adequate for the detection and
             quantitation of amyloid.

          -  Informed consent has been signed and dated by the subject/and/or subjects' legally
             acceptable representative, if applicable, in accordance with local regulations.

        Exclusion Criteria:

          -  The subject has a contraindication for MRI or PET.

          -  The subject has a known or suspected hypersensitivity/allergy to [18F]flutemetamol.

          -  The subject has participated in any clinical study using an investigational agent
             within 30 days of dosing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim A Mansfield, MS</last_name>
    <role>Study Director</role>
    <affiliation>GE Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GE Healthcare</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2010</study_first_submitted>
  <study_first_submitted_qc>January 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2010</study_first_posted>
  <results_first_submitted>March 28, 2012</results_first_submitted>
  <results_first_submitted_qc>May 2, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 5, 2012</results_first_posted>
  <last_update_submitted>June 7, 2012</last_update_submitted>
  <last_update_submitted_qc>June 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyloid</keyword>
  <keyword>NPH Normal pressure hydrocephalus</keyword>
  <keyword>PET Positron Emission Tomography</keyword>
  <keyword>SUVR Standard uptake value ratios</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocephalus</mesh_term>
    <mesh_term>Hydrocephalus, Normal Pressure</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Flutemetamol Injection</title>
          <description>[18F]flutemetamol (less than 10µg flutemetamol). The nominal activity of a single administration of [18F]flutemetamol will be 185 megabecquerels(MBq).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Flutemetamol Injection</title>
          <description>[18F]flutemetamol (less than 10µg flutemetamol). The nominal activity of a single administration of [18F]flutemetamol will be 185 megabecquerels(MBq).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Quantitative Estimates of Brain Uptake [18F]Flutemetamol and the Quantitative Immunohistochemical (IHC) Estimates of Amyloid Levels in Biopsy Samples Previously Obtained.</title>
        <description>Radiotracers have enabled the in-vivo imaging of amyloid-beta plaques in the brain, one of the histopathologic hallmarks of Alzheimer's disease (AD). Standardized uptake value ratio SUVR)is the quantitive measure of specific tracer uptake, normalized for the non-specific mean uptake in a reference region. SUVR is calculated as SUV_voi/SUV_ref with SUV being the integrated activity over a given time period for the volume of interest (SUV_voi) or reference region (SUV_ref). VOI means volume of interest and REF means reference region.</description>
        <time_frame>Post-contrast administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subject 201-0001</title>
            <description>[18F]flutemetamol Injection-less than 10µg of flutemetamol.</description>
          </group>
          <group group_id="O2">
            <title>Subject 201-0002</title>
            <description>[18F]flutemetamol Injection-less than 10µg of flutemetamol.</description>
          </group>
          <group group_id="O3">
            <title>Subject 201-0003</title>
            <description>[18F]flutemetamol Injection-less than 10µg of flutemetamol.</description>
          </group>
          <group group_id="O4">
            <title>Subject 201-0004</title>
            <description>[18F]flutemetamol Injection-less than 10µg of flutemetamol.</description>
          </group>
          <group group_id="O5">
            <title>Subject 201-0005</title>
            <description>[18F]flutemetamol Injection-less than 10µg of flutemetamol.</description>
          </group>
          <group group_id="O6">
            <title>Subject 201-0006</title>
            <description>[18F]flutemetamol Injection-less than 10µg of flutemetamol.</description>
          </group>
          <group group_id="O7">
            <title>Subject 201-0007</title>
            <description>[18F]flutemetamol Injection-less than 10µg of flutemetamol.</description>
          </group>
        </group_list>
        <measure>
          <title>Quantitative Estimates of Brain Uptake [18F]Flutemetamol and the Quantitative Immunohistochemical (IHC) Estimates of Amyloid Levels in Biopsy Samples Previously Obtained.</title>
          <description>Radiotracers have enabled the in-vivo imaging of amyloid-beta plaques in the brain, one of the histopathologic hallmarks of Alzheimer's disease (AD). Standardized uptake value ratio SUVR)is the quantitive measure of specific tracer uptake, normalized for the non-specific mean uptake in a reference region. SUVR is calculated as SUV_voi/SUV_ref with SUV being the integrated activity over a given time period for the volume of interest (SUV_voi) or reference region (SUV_ref). VOI means volume of interest and REF means reference region.</description>
          <units>Standard Uptake Value Ratio (SUVR)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Brain Region-Cerebellum-VOI surrounding biopsy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.59"/>
                    <measurement group_id="O2" value="1.56"/>
                    <measurement group_id="O3" value="1.25"/>
                    <measurement group_id="O4" value="2.17"/>
                    <measurement group_id="O5" value="2.07"/>
                    <measurement group_id="O6" value="1.39"/>
                    <measurement group_id="O7" value="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brain Region-Cerebellum-Contralateral biopsy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77"/>
                    <measurement group_id="O2" value="1.93"/>
                    <measurement group_id="O3" value="1.16"/>
                    <measurement group_id="O4" value="2.32"/>
                    <measurement group_id="O5" value="2.08"/>
                    <measurement group_id="O6" value="1.18"/>
                    <measurement group_id="O7" value="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brain Region-Cerebellum-Anterior Cingulate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.19"/>
                    <measurement group_id="O2" value="2.36"/>
                    <measurement group_id="O3" value="1.44"/>
                    <measurement group_id="O4" value="2.81"/>
                    <measurement group_id="O5" value="2.65"/>
                    <measurement group_id="O6" value="1.26"/>
                    <measurement group_id="O7" value="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brain Region-Cerebellum-Frontal Cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.24"/>
                    <measurement group_id="O2" value="2.78"/>
                    <measurement group_id="O3" value="1.32"/>
                    <measurement group_id="O4" value="2.71"/>
                    <measurement group_id="O5" value="2.74"/>
                    <measurement group_id="O6" value="1.28"/>
                    <measurement group_id="O7" value="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brain Region-Cerebellum-Lateral Temporal Cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.08"/>
                    <measurement group_id="O2" value="2.35"/>
                    <measurement group_id="O3" value="1.45"/>
                    <measurement group_id="O4" value="2.56"/>
                    <measurement group_id="O5" value="2.63"/>
                    <measurement group_id="O6" value="1.52"/>
                    <measurement group_id="O7" value="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brain Region-Cerebellum-Parietal Cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99"/>
                    <measurement group_id="O2" value="2.38"/>
                    <measurement group_id="O3" value="1.38"/>
                    <measurement group_id="O4" value="2.84"/>
                    <measurement group_id="O5" value="2.27"/>
                    <measurement group_id="O6" value="1.36"/>
                    <measurement group_id="O7" value="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brain Region-Cerebellum-Posterior Cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11"/>
                    <measurement group_id="O2" value="2.33"/>
                    <measurement group_id="O3" value="1.40"/>
                    <measurement group_id="O4" value="2.86"/>
                    <measurement group_id="O5" value="2.73"/>
                    <measurement group_id="O6" value="1.17"/>
                    <measurement group_id="O7" value="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brain Region-Cerebellum-Composite VOI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.13"/>
                    <measurement group_id="O2" value="2.48"/>
                    <measurement group_id="O3" value="1.39"/>
                    <measurement group_id="O4" value="2.74"/>
                    <measurement group_id="O5" value="2.62"/>
                    <measurement group_id="O6" value="1.34"/>
                    <measurement group_id="O7" value="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparsion Between Brain Uptake of [18F] Flutemetamol Amyloid Level From Immunohistochemistry Assay and a Stained Biopsy Tissue Specimen.</title>
        <description>This was an amyloid level estimate measured by Immunohistochemistry assay to determine the percentage of plaque area for mAb NAB228. The Immuno-histo chemical reagent was monoclonal antibody (mAB) NAB228. This is a percentage of the area of the biopsy tissue specimen that stains positive for amyloid using NAB228.</description>
        <time_frame>Post-contrast administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subject 201-0001</title>
            <description>[18F]flutemetamol Injection-(less than 10µg of flutemetamol).</description>
          </group>
          <group group_id="O2">
            <title>Subject 201-0002</title>
            <description>[18F]flutemetamol Injection-(less than 10µg of flutemetamol).</description>
          </group>
          <group group_id="O3">
            <title>Subject 201-0003</title>
            <description>[18F]flutemetamol Injection-(less than 10µg of flutemetamol).</description>
          </group>
          <group group_id="O4">
            <title>Subject 201-0004</title>
            <description>[18F]flutemetamol Injection-(less than 10µg of flutemetamol).</description>
          </group>
          <group group_id="O5">
            <title>Subject 201-0005</title>
            <description>[18F]flutemetamol Injection-(less than 10µg of flutemetamol).</description>
          </group>
          <group group_id="O6">
            <title>Subject 201-0006</title>
            <description>[18F]flutemetamol Injection-(less than 10µg of flutemetamol).</description>
          </group>
          <group group_id="O7">
            <title>Subject 201-0007</title>
            <description>[18F]flutemetamol Injection-(less than 10µg of flutemetamol).</description>
          </group>
        </group_list>
        <measure>
          <title>Comparsion Between Brain Uptake of [18F] Flutemetamol Amyloid Level From Immunohistochemistry Assay and a Stained Biopsy Tissue Specimen.</title>
          <description>This was an amyloid level estimate measured by Immunohistochemistry assay to determine the percentage of plaque area for mAb NAB228. The Immuno-histo chemical reagent was monoclonal antibody (mAB) NAB228. This is a percentage of the area of the biopsy tissue specimen that stains positive for amyloid using NAB228.</description>
          <units>Percent plaque area</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.127"/>
                    <measurement group_id="O2" value="0.447"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1.007"/>
                    <measurement group_id="O5" value="0.4"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quantitative Estimates of Amyloid Levels ( Percent % Plaque Load) for the Following 7 Subjects</title>
        <description>Using the Precent area of Plaque values from the Primary Anaylsis, determine the association between cerebral cortical uptake of [18F] flutemetamol (as contralateral, ipsilateral, and composite SUVR values) and Immunohistochemical and histochemical-based estimates of amyloid.</description>
        <time_frame>Post-contrast Administration</time_frame>
        <population>Using the Precent area of Plaque values from the Primary Anaylsis, determine the association between cerebral cortical uptake of [18F] flutemetamol (as contralateral, ipsilateral, and composite SUVR values) and Immunohistochemical and histochemical-based estimates of amyloid.</population>
        <group_list>
          <group group_id="O1">
            <title>Amyloid Level (Plaque Load)</title>
            <description>Amlyoid level estimate from the Immunohistochemistry assay: Percent plaque area (average across slides) for mAb NAB228.</description>
          </group>
        </group_list>
        <measure>
          <title>Quantitative Estimates of Amyloid Levels ( Percent % Plaque Load) for the Following 7 Subjects</title>
          <description>Using the Precent area of Plaque values from the Primary Anaylsis, determine the association between cerebral cortical uptake of [18F] flutemetamol (as contralateral, ipsilateral, and composite SUVR values) and Immunohistochemical and histochemical-based estimates of amyloid.</description>
          <population>Using the Precent area of Plaque values from the Primary Anaylsis, determine the association between cerebral cortical uptake of [18F] flutemetamol (as contralateral, ipsilateral, and composite SUVR values) and Immunohistochemical and histochemical-based estimates of amyloid.</population>
          <units>Percentage of Plaque</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subject-201-0001</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject-201-0002</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject-201-0003</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject-201-0004</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject-201-0005</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject-201-0006</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject-201-0007</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Contralateral to the biopsy Site</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The level of association between SUVR and the amyloid levels was analyzed using a regression model.</non_inferiority_desc>
            <p_value>0.098</p_value>
            <method>Regression, Linear</method>
            <param_type>R²</param_type>
            <param_value>0.688</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Ipsilateral to the biopsy Site</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The level of association between SUVR and the amyloid levels was analyzed using a regression model.</non_inferiority_desc>
            <p_value>0.268</p_value>
            <method>Regression, Linear</method>
            <param_type>R²</param_type>
            <param_value>0.482</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Composite Region</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The level of association between SUVR and the amyloid levels was analyzed using a regression model.</non_inferiority_desc>
            <p_value>0.099</p_value>
            <method>Regression, Linear</method>
            <param_type>R²</param_type>
            <param_value>0.685</param_value>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Flutemetamol Injection</title>
          <description>[18F]flutemetamol (less than 10µg flutemetamol). The nominal activity of a single administration of [18F]flutemetamol will be 185 megabecquerels(MBq).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Pressure Increase</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood Glucose Decrease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Paul Sherwin, MD</name_or_title>
      <organization>GE Healthcare</organization>
      <phone>1-609-514-6820</phone>
      <email>paulsherwin@ge.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

